See more : Middle East Healthcare Company (4009.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Vertex Pharmaceuticals Incorporated (VX1.DE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vertex Pharmaceuticals Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
- Silver Storm Mining Ltd. (SVRS.V) Income Statement Analysis – Financial Results
- PGS ASA (PGS.OL) Income Statement Analysis – Financial Results
- Repsol, S.A. (REP.MC) Income Statement Analysis – Financial Results
- iFabric Corp. (IFA.TO) Income Statement Analysis – Financial Results
- Fincantieri S.p.A. (FNCNF) Income Statement Analysis – Financial Results
Vertex Pharmaceuticals Incorporated (VX1.DE)
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.87B | 8.93B | 7.57B | 6.21B | 4.16B | 3.05B | 2.49B | 1.70B | 1.03B | 580.42M | 1.21B | 1.53B | 1.41B | 143.37M | 102.05M | 175.50M | 199.01M | 216.36M | 160.89M | 102.72M | 69.14M | 161.09M | 167.49M | 78.13M | 61.60M | 44.40M | 43.80M | 13.30M | 22.10M | 19.60M | 27.90M | 3.80M | 3.20M | 2.30M |
| Cost of Revenue | 4.43B | 1.08B | 904.20M | 736.30M | 547.76M | 409.54M | 275.12M | 210.46M | 125.54M | 60.99M | 130.28M | 279.89M | 80.51M | 12.73M | 14.20M | 15.69M | 13.90M | 12.17M | 10.10M | 5.65M | 3.13M | 28.28M | 39.63M | 4.08M | -3.40M | -4.50M | -3.60M | -3.20M | -3.70M | -3.50M | -3.90M | -2.80M | -1.80M | 0.00 |
| Gross Profit | 5.44B | 7.85B | 6.67B | 5.47B | 3.62B | 2.64B | 2.21B | 1.49B | 906.79M | 519.43M | 1.08B | 1.25B | 1.33B | 130.64M | 87.85M | 159.82M | 185.11M | 204.19M | 150.79M | 97.07M | 66.02M | 132.80M | 127.86M | 74.05M | 65.00M | 48.90M | 47.40M | 16.50M | 25.80M | 23.10M | 31.80M | 6.60M | 5.00M | 2.30M |
| Gross Profit Ratio | 55.16% | 87.90% | 88.06% | 88.14% | 86.84% | 86.56% | 88.95% | 87.64% | 87.84% | 89.49% | 89.25% | 81.67% | 94.29% | 91.12% | 86.08% | 91.06% | 93.01% | 94.38% | 93.72% | 94.50% | 95.48% | 82.44% | 76.34% | 94.78% | 105.52% | 110.14% | 108.22% | 124.06% | 116.74% | 117.86% | 113.98% | 173.68% | 156.25% | 100.00% |
| Research & Development | 3.69B | 2.54B | 3.05B | 1.83B | 1.75B | 1.42B | 1.32B | 1.05B | 996.17M | 855.51M | 918.78M | 806.19M | 707.71M | 637.42M | 550.69M | 516.29M | 513.05M | 371.71M | 248.54M | 192.16M | 199.64M | 203.02M | 148.67M | 84.92M | 72.20M | 58.70M | 51.60M | 35.20M | 41.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 557.62M | 496.08M | 432.83M | 376.58M | 305.41M | 362.34M | 436.80M | 400.72M | 187.80M | 130.19M | 101.91M | 84.73M | 57.86M | 43.99M | 42.14M | 39.08M | 49.39M | 47.34M | 27.81M | 26.10M | 18.10M | 11.40M | 7.90M | 7.10M | 40.30M | 26.70M | 13.80M | 8.80M | 6.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31.40M | 505.00K | 16.20M | 19.60M | 0.00 | 0.00 | 0.00 | -895.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.14B | 944.70M | 840.10M | 770.46M | 658.50M | 557.62M | 496.08M | 432.83M | 377.08M | 305.41M | 362.34M | 436.80M | 400.72M | 187.80M | 129.30M | 101.91M | 84.73M | 57.86M | 43.99M | 42.14M | 39.08M | 49.39M | 47.34M | 27.81M | 26.10M | 18.10M | 11.40M | 7.90M | 7.10M | 40.30M | 26.70M | 13.80M | 8.80M | 6.40M |
| Other Expenses | -3.21B | -164.80M | 4.90M | 296.42M | 192.18M | -790.00K | -81.38M | 4.13M | -6.71M | 30.40M | -72.67M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.30M | 4.50M | 3.60M | 3.20M | 3.70M | 3.50M | 3.90M | 2.80M | 1.80M | 0.00 |
| Operating Expenses | 1.61B | 3.49B | 3.89B | 2.60B | 2.41B | 1.97B | 1.82B | 1.48B | 1.37B | 1.16B | 1.28B | 1.24B | 1.11B | 825.22M | 679.98M | 618.20M | 597.78M | 429.57M | 292.53M | 234.30M | 238.72M | 252.41M | 196.01M | 112.73M | 104.60M | 81.30M | 66.60M | 46.30M | 52.30M | 43.80M | 30.60M | 16.60M | 10.60M | 6.40M |
| Cost & Expenses | 6.04B | 4.57B | 4.80B | 3.34B | 2.96B | 2.38B | 2.10B | 1.69B | 1.50B | 1.22B | 1.41B | 1.52B | 1.19B | 837.95M | 694.18M | 633.89M | 611.69M | 441.74M | 302.63M | 239.95M | 241.84M | 280.69M | 235.64M | 116.81M | 101.20M | 76.80M | 63.00M | 43.10M | 48.60M | 40.30M | 26.70M | 13.80M | 8.80M | 6.40M |
| Interest Income | 614.70M | 144.60M | 4.90M | 22.24M | 63.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.94M | 1.88M | 1.96M | 5.01M | 16.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 44.10M | 54.80M | 61.50M | 58.15M | 58.50M | 34.12M | 57.55M | 81.43M | 84.21M | 72.86M | 22.73M | 14.71M | 36.57M | 19.28M | 13.19M | 13.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 181.30M | 148.30M | 125.60M | 109.50M | 106.94M | 72.42M | 61.40M | 61.40M | 62.34M | 63.26M | 48.37M | 38.19M | 35.04M | 30.46M | 30.11M | 32.20M | 27.46M | 25.87M | 27.29M | 29.64M | 23.44M | 25.43M | 17.96M | 9.10M | 6.30M | 4.50M | 3.60M | 3.20M | 3.70M | 3.50M | 3.90M | 2.80M | 1.80M | 0.00 |
| EBITDA | 4.61B | 4.53B | 4.02B | 3.16B | 1.31B | 736.39M | 454.23M | 72.60M | -411.25M | -598.76M | -554.75M | 85.23M | 133.17M | -662.16M | -598.88M | -426.19M | -385.21M | -201.90M | -114.45M | -107.59M | -149.27M | -123.05M | -97.14M | -24.65M | -44.30M | -43.20M | -15.60M | -36.30M | -22.80M | -17.20M | 5.10M | -7.20M | -3.80M | -4.10M |
| EBITDA Ratio | 46.66% | 48.65% | 36.82% | 51.37% | 35.02% | 21.76% | 12.51% | 0.90% | -45.83% | -105.28% | 41.63% | 0.27% | 15.72% | -461.86% | -531.80% | -260.35% | -189.99% | -93.32% | -56.52% | -101.15% | -96.10% | -58.43% | -14.39% | -18.77% | -52.92% | -62.84% | -35.62% | -127.07% | -128.05% | -106.12% | 13.26% | -242.11% | -143.75% | -178.26% |
| Operating Income | 3.83B | 4.31B | 2.78B | 2.86B | 1.20B | 635.15M | 123.24M | 9.94M | -468.66M | -692.41M | -903.45M | 2.33M | 113.82M | -696.08M | -613.41M | -462.71M | -419.79M | -229.04M | -149.87M | -154.81M | -264.53M | -119.60M | -91.80M | -38.68M | -39.60M | -32.40M | -19.20M | -29.80M | -26.50M | -20.70M | 1.20M | -10.00M | -5.60M | -4.10M |
| Operating Income Ratio | 38.83% | 48.23% | 36.73% | 46.03% | 28.77% | 20.84% | 4.95% | 0.58% | -45.40% | -119.30% | -74.54% | 0.15% | 8.07% | -485.51% | -601.10% | -263.65% | -210.94% | -105.86% | -93.15% | -150.71% | -382.59% | -74.25% | -54.81% | -49.51% | -64.29% | -72.97% | -43.84% | -224.06% | -119.91% | -105.61% | 4.30% | -263.16% | -175.00% | -178.26% |
| Total Other Income/Expenses | 547.80M | -75.00M | -51.70M | 260.50M | 197.42M | -34.91M | -138.93M | -77.30M | -90.92M | -42.46M | -16.04M | -14.73M | -53.38M | -58.55M | -28.77M | -1.47M | -7.12M | 2.38M | -23.52M | -3.70M | -82.82M | 28.30M | -2.79M | -16.16M | 10.30M | 0.00 | 0.00 | 0.00 | 5.50M | 3.60M | 900.00K | 2.00M | 800.00K | 4.10M |
| Income Before Tax | 4.38B | 4.23B | 2.73B | 3.12B | 1.39B | 600.24M | -15.69M | -67.37M | -559.58M | -734.88M | -976.12M | -12.38M | 60.45M | -754.63M | -662.86M | -464.18M | -426.91M | -226.66M | -173.39M | -158.51M | -347.35M | -119.66M | -117.89M | -53.61M | -40.30M | 0.00 | 0.00 | -39.50M | -21.00M | -17.10M | 2.10M | -8.00M | -4.80M | 0.00 |
| Income Before Tax Ratio | 44.38% | 47.39% | 36.05% | 50.22% | 33.51% | 19.70% | -0.63% | -3.96% | -54.21% | -126.61% | -80.54% | -0.81% | 4.28% | -526.35% | -649.55% | -264.48% | -214.52% | -104.76% | -107.77% | -154.31% | -502.38% | -74.28% | -70.39% | -68.62% | -65.42% | 0.00% | 0.00% | -296.99% | -95.02% | -87.24% | 7.53% | -210.53% | -150.00% | 0.00% |
| Income Tax Expense | 760.20M | 910.40M | 388.30M | 405.15M | 218.11M | -1.49B | -107.32M | 16.67M | 30.38M | 6.96M | -288.57M | 38.75M | 19.27M | 19.28M | 19.34M | -30.73M | -21.39M | -18.50M | 61.68M | 29.01M | 24.06M | -10.98M | -1.92M | 976.00K | 1.40M | 700.00K | 600.00K | 10.20M | -5.00M | -3.10M | 100.00K | -1.50M | -500.00K | 4.30M |
| Net Income | 3.62B | 3.32B | 2.34B | 2.71B | 1.18B | 2.10B | 263.48M | -112.05M | -558.12M | -738.56M | -445.03M | -107.03M | 29.57M | -754.63M | -641.58M | -459.85M | -391.28M | -206.89M | -203.42M | -166.25M | -196.77M | -108.62M | -66.23M | -39.66M | -41.00M | -33.10M | -19.80M | -40.00M | -21.50M | -17.60M | 2.00M | -8.50M | -5.10M | -4.30M |
| Net Income Ratio | 36.68% | 37.20% | 30.92% | 43.70% | 28.27% | 68.80% | 10.59% | -6.58% | -54.06% | -127.25% | -36.72% | -7.01% | 2.10% | -526.35% | -628.70% | -262.02% | -196.61% | -95.63% | -126.43% | -161.85% | -284.59% | -67.43% | -39.54% | -50.76% | -66.56% | -74.55% | -45.21% | -300.75% | -97.29% | -89.80% | 7.17% | -223.68% | -159.38% | -186.96% |
| EPS | 13.89 | 12.78 | 9.09 | 10.44 | 4.58 | 8.25 | 1.06 | -0.46 | -2.31 | -3.14 | -1.98 | -0.50 | 0.14 | -3.77 | -3.70 | -3.27 | -3.03 | -1.83 | -2.28 | -2.12 | -2.56 | -1.43 | -0.89 | -0.59 | -0.80 | -0.65 | -0.41 | -1.07 | -0.63 | -0.56 | 0.08 | -0.35 | -0.35 | -0.33 |
| EPS Diluted | 13.89 | 12.78 | 9.01 | 10.29 | 4.51 | 8.09 | 1.04 | -0.46 | -2.31 | -3.14 | -1.98 | -0.50 | 0.14 | -3.77 | -3.70 | -3.27 | -3.03 | -1.83 | -2.28 | -2.12 | -2.56 | -1.43 | -0.89 | -0.59 | -0.80 | -0.65 | -0.41 | -1.07 | -0.63 | -0.56 | 0.08 | -0.35 | -0.35 | -0.33 |
| Weighted Avg Shares Out | 260.59M | 256.10M | 257.70M | 259.80M | 256.70M | 254.29M | 248.86M | 244.69M | 241.31M | 235.31M | 224.91M | 211.95M | 204.89M | 200.40M | 173.26M | 140.56M | 128.99M | 113.22M | 89.24M | 78.57M | 77.00M | 75.75M | 74.46M | 67.68M | 51.04M | 50.60M | 48.53M | 37.38M | 34.13M | 31.43M | 25.00M | 24.29M | 14.62M | 13.03M |
| Weighted Avg Shares Out (Dil) | 260.50M | 259.84M | 259.90M | 263.40M | 260.70M | 259.19M | 253.23M | 244.69M | 241.31M | 235.31M | 224.91M | 215.26M | 208.81M | 200.40M | 173.26M | 140.56M | 128.99M | 113.22M | 89.24M | 78.57M | 77.00M | 75.75M | 74.46M | 67.68M | 51.04M | 50.60M | 48.53M | 37.38M | 34.13M | 31.43M | 25.00M | 24.29M | 14.62M | 13.03M |
Source: https://incomestatements.info
Category: Stock Reports